Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
1994-7-7
pubmed:abstractText
A series of polyhydroxylated 2-phenylbenzothiazoles 3 has been prepared by demethylation of the precursor methoxylated 2-phenylbenzothiazoles 9. The key step in the construction of the benzothiazole nucleus involves a Jacobson cyclization of methoxylated thiobenzanilides 8. The target compounds inhibit WiDr human colon tumor cells and MCF-7 human mammary tumor cells in vitro with IC50 values in the low micromolar range, but the activity against MCF-7 cells is not related to estrogen receptor-binding affinity. None of the compounds showed selective cytotoxicity against Abelson virus-transformed ANN-1 cells encoded with the pp120gag-abl tyrosine kinase compared with the parental 3T3 line. Compounds were only marginally inhibitory to the EGF receptor-associated protein tyrosine kinase from a membrane preparation of A431 cells. The most active compound was 4,6-dihydroxy-2-(4-hydroxyphenyl)benzothiazole (3b) which has the same overall hydroxyl substitution pattern as genistein (1a). The compounds were weakly cytotoxic for an EGF receptor, overexpressing cell line HN5, but when tested for differential toxicity against the EGF receptor tyrosine kinase or the PDGF receptor tyrosine kinase in a standard mitogenesis assay utilizing human fibroblasts, no discrimination was observed. In this assay, the compounds inhibited DNA synthesis when added to cells during S phase. This suggests that inhibition could not be interpreted in terms of tyrosine kinase inactivation but more likely as a relatively broad specificity for the ATP-binding domain of other kinases such as thymidine kinase.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0022-2623
pubmed:author
pubmed:issnType
Print
pubmed:day
27
pubmed:volume
37
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1689-95
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:8201603-3T3 Cells, pubmed-meshheading:8201603-Animals, pubmed-meshheading:8201603-Antineoplastic Agents, pubmed-meshheading:8201603-Breast Neoplasms, pubmed-meshheading:8201603-Cell Division, pubmed-meshheading:8201603-Colonic Neoplasms, pubmed-meshheading:8201603-Fibroblasts, pubmed-meshheading:8201603-Genistein, pubmed-meshheading:8201603-Humans, pubmed-meshheading:8201603-Hydroxylation, pubmed-meshheading:8201603-Isoflavones, pubmed-meshheading:8201603-Mice, pubmed-meshheading:8201603-Molecular Structure, pubmed-meshheading:8201603-Protein-Tyrosine Kinases, pubmed-meshheading:8201603-Quercetin, pubmed-meshheading:8201603-Receptor, Epidermal Growth Factor, pubmed-meshheading:8201603-Structure-Activity Relationship, pubmed-meshheading:8201603-Thiazoles, pubmed-meshheading:8201603-Tumor Cells, Cultured
pubmed:year
1994
pubmed:articleTitle
Structural studies on bioactive compounds. 23. Synthesis of polyhydroxylated 2-phenylbenzothiazoles and a comparison of their cytotoxicities and pharmacological properties with genistein and quercetin.
pubmed:affiliation
Department of Pharmaceutical Sciences, University of Nottingham, U.K.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't